Recent Research Analysts’ Ratings Changes for MBX Biosciences (MBX)

A number of research firms have changed their ratings and price targets for MBX Biosciences (NASDAQ: MBX):

• 5/17/2026 – MBX Biosciences was downgraded by Wall Street Zen from “hold” to “sell”.
• 5/12/2026 – MBX Biosciences was given a new $56.00 price target by Stifel Nicolaus.
• 5/12/2026 – MBX Biosciences had its price target raised by Barclays PLC from $66.00 to $70.00. They now have an “overweight” rating on the stock.
• 5/12/2026 – MBX Biosciences had its “outperform” rating reaffirmed by Citigroup Inc..
• 5/12/2026 – MBX Biosciences had its price target raised by Citizens Jmp from $76.00 to $86.00. They now have a “market outperform” rating on the stock.
• 5/11/2026 – MBX Biosciences had its price target raised by Truist Financial Corporation from $50.00 to $70.00. They now have a “buy” rating on the stock.
• 5/9/2026 – MBX Biosciences was upgraded by Wall Street Zen from “sell” to “hold”.
• 4/21/2026 – MBX Biosciences had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/11/2026 – MBX Biosciences was downgraded by Wall Street Zen from “hold” to “sell”.
• 3/31/2026 – MBX Biosciences was upgraded by Lifesci Capital to “strong-buy”.

Insider Buying and Selling

In other news, CEO P. Kent Hawryluk bought 18,500 shares of MBX Biosciences stock in a transaction on Friday, March 13th. The stock was acquired at an average cost of $28.41 per share, for a total transaction of $525,585.00. Following the completion of the acquisition, the chief executive officer owned 486,777 shares of the company’s stock, valued at $13,829,334.57. This trade represents a 3.95% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 52.19% of the company’s stock.

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.